GRFS Stock Recent News

Does Grifols (GRFS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Stevanato Group (STVN). But which of these two stocks offers value investors a better bang for their buck right now?

NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 3% of Grifols S.A. (“Grifols” or the “Company”) (BME: GRF) (NASDAQ: GRFS) class A shares, today announced that it sent a letter to the Grifols Board of Directors (the “Board”) expressing Mason's support for the Company's recommended slate of director candidates for election at the Ordinary General Shareholders' Meeting to be held on June 4 and 5, 2025. T.

A New York court found enough evidence to continue with the defamation lawsuit filed by Spanish pharmaceutical company Grifols against short seller Gotham City Research, Grifols said in a statement on Friday.

At current levels, GRFS scores over ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum.

Grifols offers compelling long-term upside, with potential returns exceeding 200% as the company recovers and grows earnings. Recent Q1 2025 results confirm strong operational recovery: top-line growth, improved margins, and significant debt reduction, supporting my continued conviction. The primary risk is high leverage, but ongoing cash flow improvements and no dividend payout allow to focus on deleveraging, with dividend restoration likely by 2026.

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Grifols (GRFS) and Neurocrine Biosciences (NBIX). But which of these two stocks presents investors with the better value opportunity right now?

Grifols, S.A. (NASDAQ:GRFS ) Q1 2025 Earnings Conference Call May 12, 2025 12:30 PM ET Company Participants Danny Segarra - VP, IR and Sustainability Nacho Abia - CEO Rahul Srinivasan - CFO Roland Wandeler - President Biopharma Conference Call Participants Charles Pitman - Barclays Alvaro Lenze - Alantra Equities Jaime Escribano - Banco Santander Guilherme Sampaio - CaixaBank Danny Segarra Hello, everyone.

Grifols's net profit almost tripled from a year earlier, which the Spanish drugmaker said reinforced its confidence in meeting its full-year guidance.